Incubation for a short time of arachidonic acid with the microsomal fraction of a homogenate of the vesicular gland of sheep in the presence of 1 mM p-mercuribenzoate followed by extraction and silicic acid chromatography yielded two prostaglandin endoperoxides. The structures of these compounds, i.e., 15-hydroperoxy-9a,11a-peroxidoprosta-5,13-dienoic acid (prostaglandin G2) and 15-hydroxy-9a,lla-peroxidoprosta-5,13-dienoic acid (prostaglandin H2), were assigned mainly by a number of chemical transformations into previously known prostaglandins. The new prostaglandins were 50-200 times (prostaglandin G2) and 100-450 times (prostaglandin H2) more active than prostaglandin E2 on the superfused aorta strip. The half-life of the prostaglandin endoperoxides in aqueous medium (about 5 min) was significantly longer than that of "rabbit aorta-contracting substance" released from guinea pig lung, indicating that none of the prostaglandin endoperoxides is identical with this factor. Addition of 10-300 ng/ml of the endoperoxides to suspensions of washed human platelets resulted in rapid aggregation. Furthermore, platelet aggregation induced by thrombin was accompanied by release of material reducible by stannous chloride into prostaglandin F2a, thus indicating the involvement of endogenous prostaglandin endoperoxides in platelet aggregation.
Direct evidence for the formation of an endoperoxide during prostaglandin (PG) biosynthesis was recently obtained (1) . In these experiments a compound, reducible to PGF2, could be detected in incubations of arachidonic acid for a short time with the microsomal fraction of a homogenate of the vesicular gland of sheep. Preincubation with p-mercuribenzoate and other SH blocking agents reduced the rate of formation of PGE2 as well as the rate of disappearance of the intermediate. This compound was also isolated by solvent extraction and thin-layer chromatography and was found to be a 15-hydroxy prostaglandin endoperoxide (1) .
The present paper is concerned with isolation and determination of the structure of an additional prostaglandin endoperoxide having a hydroperoxy group at C-15, as well as the effect of the 15-hydroperoxy and 15-hydroxy endoperoxides on platelet aggregation and rabbit aorta strip.
MATERIALS AND METHODS
[1_-4C]Arachidonic acid, specific radioactivity about 11 Ci/ mol, was prepared from 1-chloro-4,7,10,13-nonadecatetraene Abbreviations: PGEI, prostaglandin El; PGE2, prostaglandin E2; PGF2, prostaglandin F2,; PGG2, prostaglandin G2; PGH2, prostaglandin H2; TLC, thin-layer chromatography; GLC, gasliquid chromatography; Me3Si, trimethylsilyl; MO, 0-methyloxime.
(kindly provided by Dr. W. Stoffel, Cologne, Germany, see ref.
2) and Na14CN followed by hydrolysis of the nitrile. The chemical and radiochemical purity was in excess of 98%, as judged by thin-layer radiochromatography. Part of the labeled acid was diluted with unlabeled material to make a preparation with specific radioactivity of 0.77 Ci/mol, which was used for incubations with vesicular gland microsomes.
Thin-Layer Chromatography (TLC) was carried out with plates coated with chloroform-methanol-washed Silica immediately dissolved in about 3 ml of diethyl ether-light petroleum (2:8, v/v) and subjected to silicic acid chromatography.
Platelet Aggregation. Blood of healthy donors who had not taken aspirin for 1 week was collected with 7.5% (v/v) of 77 mM sodium EDTA and centrifuged at 200 X g for 15 min. The platelet-rich plasma thus obtained (280,000-400,000 platelets per ul) was centrifuged at 650 X g for 15 min. The platelet pellet from 12 ml of platelet-rich plasma was suspended in 5 ml of 0.15 M NaCl-0.15 M Tris* HC1 buffer pH 7.4-0.077 M sodium EDTA (90:8:2, v/v/v) and subsequently recentrifuged. The pellet of washed platelets was suspended in 4 ml of Krebs-Henseleit medium (3) not containing calcium. Platelet aggregation was monitored with a Born aggregometer (4). To 1 ml of platelet suspensions at 37°were added prostaglandin endoperoxides (10- for different times before addition to the strip (about 400 ,ul added by drops during 15 see). Fig. 1 shows a silicic acid chromatography of the material isolated after incubation of [1-14C] arachidonic acid with the microsomal preparation. The fractions corresponding to the major peaks of radioactivity were pooled and taken to dryness. The residue was dissolved in 0.5 ml of dry acetone, and aliquots were subjected to TLC (Fig. 1) . The two compounds isolated appeared to be stable in dry diethyl ether and acetone at -20°. However, the presence of a sensitive peroxide group in both compounds was indicated by the rapid degradation induced by addition of water or ethanol. The less-polar compound (yield from [1-14C] 24.2) gave a mass spectrum identical to that of the MOMe3Si derivative of a sample of methyl 9a,11a-dihydroxy-15-ketoprosta-5,13-dienoate (7).
RESULTS
Isomerization in Aqueous Medium: Formation of 15-Hydroperoxy-PGE2. PGG2 (150 Mug) in 0.5 ml of acetone was added to 10 ml of potassium phosphate buffer pH 7.4 and kept at room temperature for 4 hr. The product isolated by extraction with diethyl ether was treated with diazomethane and subjected to TLC. A major peak (60-70% of the applied radioactivity, RF = 0.30) and several minor peaks of less polar derivatives appeared. The major compound was assigned the structure 1 1-hydroxy-1 5-hydroperoxy-9-ketoprosta-5,13-dienoic acid (methyl ester) on the basis of the following experiments. Reduction with 10 mg of SnCl2 in 2 ml of methanol gave a single component that chromatographed with the methyl ester of PGE2 (RF = 0.10). This material was conclusively identified as the methyl ester of PGE2 by analysis of the MO-Me3Si derivative by GLC-mass spectrometry.
In another experiment, the isomerization product was treated with sodium borodeuteride (98% deuterium, Merck, Sharp, and Dohme, Quebec, Canada) and subsequently subjected to TLC (solvent: water-saturated ethyl acetate). Two peaks of radioactivity in proportions 1:1 appeared (RF = 0.35 and 0.23, chromatographing with the methyl esters of PGF2, and PGF2,6, respectively). The mass spectra recorded on the Me3Si derivatives showed a molecular ion at m/e 585 (unlabeled derivatives, m/e 584), i.e., 1 atom of deuterium was incorporated in the borodeuteride reduction. The ion at m/e 218 (Me3SiO+=C2H-CH=CH-OSiMe3) supported the location of this deuterium at C-9.
Structure of prostaglandin H2 (Fig. 2) The identity of PGH2 with the previously isolated 15-hydioxy endoperoxide (1) PGG2 and PGH2 induced aggregation of human blood platelets (Fig. 3) . The extent as well as the reversibility of the aggregation was dependent upon the concentration of the endoperoxides, i.e., small amounts (about 10 ng/ml) gave a small and reversible aggregation whereas higher concentrations (50-300 ng/ml) gave a pronounced aggregation that was reversible only to a small extent. Linear relationships between log concentration and maximum aggregation were obtained for both compounds in the concentration range 10-300 ng/ml. The relative potency of PGG2 and PGH2 was about 3:1. Preincubation for 1 min with 50 ug/inl of aspirin gave no significant change in the maximum aggregation induced by PGG2 or PGH2. However, a somewhat greater initial slope as well as an increased reversibility were seen in the presence of aspirin (Fig. 3) , suggesting stimulation of the first phase and inhibition of the second phase of aggregation (8) .
In order to explore whether prostaglandin endoperoxides are released during platelet aggregation, the following experi_0t .
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;__ H ments were done. Four milliliters of platelet suspension were treated with 20 units of thrombin at 37°. One min after the addition of thrombin, the clumped platelets were removed by filtration under reduced pressure and samples of 1 ml of the filtrate were removed and added (2.5-3.5 min after addition of thrombin) to 15 ml of ethanol and to 15 ml of ethanol containing 75 mg of SnCl2. PGF2a was determined in these solutions by multiple-ion analysis with [3, 3, 4, 4 -2H4]PGF2, as carrier (9) . The amount in the nonreduced platelet medium was 11.7 + 1.9 ng/ml (three experiments) and in the reduced medium 30.2 ± 6.3 ng/ml (three experiments), indicating the presence of PGG2 and/or PGH2.
Stimulation of rabbit aorta strip
The prostaglandin endoperoxides both stimulated the superfused aorta strip. Linear relationships between log concentration and contractile force were obtained in the concentration range 10-700 ng/ml. The possible to obtain the compounds in pure form (Fig. 1) . We suggest the trivial names prostaglandin G2 (PGG2) for the less-polar endoperoxide (15-hydroperoxy-9a,1 1 a-peroxidoprosta-5,13-dienoic acid) and prostaglandin H2 (PGH2) for the more-polar endoperoxide (15-hydroxy-9a,11a-peroxidoprosta-5,13-dienoic acid). The conversion of 8,11,14-eicosatrienoic acid into analogous endoperoxides, i.e., prostaglandins Gi and Hi, has recently been demonstrated.* The structure of PGG2 was established by three sets of experiments (Fig. 2) . Treatment of PGG2 with mild reducing agents such as SnCl2 and triphenylphosphine gave PGF2a as major product. This result showed the presence of a peroxide bridge between C-9 and C-11 but did not discriminate between a hydroxy and a hydroperoxy group at C-15 since the agents used wvould reduce the latter group into the former. In a second experiment, PGG2 was treated with lead tetraacetate in benzene followed by triphenylphosphine. In this case, 15-keto-PGF2 was the major product. Lead tetraacetate effects dehydration of hydroperoxides into ketones (10) and, therefore, formation of a 15-keto prostaglandin from PGG2 by this treatment strongly indicated the presence of a hydroperoxy group at C-15. The isomerization of PGG2 into 15-hydroperoxy-PGE2 in aqueous medium gave independent evidence for a peroxide bridge between C-9 and C-11 and proved the presence of a hydroperoxy group at C-15.
PGH2 was found to be identical with the previously isolated 15-hydroxy prostaglandin endoperoxide by several criteria, e.g., TLC, reduction with SnCI2 and triphenylphosphine (yielding PGF2a), isomerization in aqueous medium (yielding PGE2 as main product), and isomerization by silica gel of the methyl ester into the methyl esters of 11-dehydro-PGF2a and PGE2.
It seems likely that PGG2 is the first stable compound formed from arachidonic acid by the "prostaglandin synthetase." By the isolation of PGG2 it was demonstrated for the first time that introduction of the oxygen function at C-15 of the prostaglandins occurs by a dioxygenase reaction. We propose the name fatty acid cyclo-oxygenase for the enzyme(s) that catalyzes the conversion of arachidonic acid into PGG2 by oxygenation at C-11 and C-15.
The high biological potency of the new prostaglandins was exemplified by their stimulating activity on the rabbit aorta. PGG2 was 50-200 times and PGH2 100-450 times, more potent than PGE2. "Rabbit aorta-contracting substance" released from guinea pig lung (11, 12) was recently found to have a half-life significantly shorter than that of PGG2 and PGH2 (about 5 min) t, indicating that none of the prostaglandin endoperoxides is identical with this factor (13) .
PGE, inhibits platelet aggregation by stimulation of adenylate cyclase (14) . PGE2 has been reported to exert a double effect: a PGE1-like effect on the first phase of aggregation (probably by stimulation of adenylate cyclase) followed bv a stimulatorv effect on the second phase of aggregation (15) . In the absence of agents capable of inducing platelet aggregation, no effect is seen by either PGE, or PGE2. The new prostaglandins PGG2 and PGH2, however, induced rapid aggregation when they were added to a platelet suspension. The relative potency of PGG2 and PGH2 was about 3:1. Our findings that PGG2 and/or PGH2 are formed during thrombin-induced aggregation and that they are powerful aggregating agents indicate that they play a role in platelet aggregation. Aspirin, an inhibitor of prostaglandin biosynthesis in platelets (16) , has been reported to inhibit the second phase of platelet aggregation (8) . It is suggested that this effect is due to inhibited formation of PGG2 and PGH2 from arachidonic acid within the platelet. 
